pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma
Philogen
Philogen S.p.A.
Philogen trial registry — 18 ClinicalTrials.gov studies with program phase, status, and indication context.
Loc. Bellaria, 35, Sovicille, SIENA 53018, IT HQ
1996 Founded
180 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Loc. Bellaria, 35, Sovicille, SIENA 53018, IT
- Founded
- 1996
- Employees
- 180
- Programs
- 18
- Drugs
- 29
- Patents
- 0
Philogen clinical trials
Registry index of 18 ClinicalTrials.gov studies linked to Philogen programs — each row shows trial ID, program name, phase, status, and indication.
Philogen trial registry — 18 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Philogen.
-
PH-L19TNFDOX2-03/16 — Phase 3
Clinical update -
PH-F8IL10INTRA-03/24 — Phase 1
Clinical update -
PH-CAIXGA-02/24 — Phase 1
Clinical update -
PH-ACP3GA-03/25 — Phase 1
Clinical update -
PH-ACP3GA-01/24 — Phase 1
Clinical update -
PH-L19TNFSARC-03/18 — Phase 2
Clinical update -
PH-L19IL2CORK-01/25 — Phase 1
Clinical update -
PH-ICKPD1-02/21 — Phase 2
Clinical update
Trial registry
-
CTIS ↗ - 2024-510841-32-00CTIS ↗
Safety and Early Signs of Efficacy of IL12-L19L19
Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy
- 2024-512704-20-00CTIS ↗
PH-L19TNFSARC-03/18
Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.
-
CTIS ↗ -
CTIS ↗ - 2024-515608-38-00CTIS ↗
PH-ACP3GA-01/24
Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
-
CTIS ↗ - 2024-515749-40-00CTIS ↗
Darleukin, Fibromun
Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions
-
CTIS ↗ - 2024-517896-19-00CTIS ↗
PH-F8IL10INTRA-03/24
Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.
- 2024-518530-92-00CTIS ↗
Darleukin, Fibromun
Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.
- 2024-518531-10-00CTIS ↗
Fibromun, Darleukin
Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)
- 2024-519326-20-00CTIS ↗
PH-ICKPD1-02/21
Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy
- 2025-522243-17-00CTIS ↗
PH-L19IL2CORK-01/25
Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma
-
CTIS ↗ - 2025-523230-77-00CTIS ↗
Fibromun, Darleukin
Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.
-
CTIS ↗ - 2025-524594-16-00CTIS ↗
PH-ACP3GA-03/25
Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands